Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

tvtn

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, and Zee Media—she has consistently reported on the intersection of public health policy, corporate healthcare, and the pharmaceutical industry. Her journalism spans policy deep dives, industry trends, regulatory shifts, and corporate strategy across India’s thriving hea...

SHOW MORE...

Novartis has over 9,000 employees in India

Novartis expands India development hubs as global pipeline grows

by Neetu Chandra Sharma |Dec 4, 2025

The company is evaluating obesity pipeline but ruled out ‘me-too’ GLP-1 or GIP drugs.

IQVIA and AWS said the collaboration reflects the growing need for cloud-based tools

IQVIA aligns with AWS to expand cloud-based clinical trial tools

by Neetu Chandra Sharma |Dec 3, 2025

IQVIA and AWS said the collaboration reflects the growing need for cloud-based tools that can support large-scale trial operations and analytical workloads.

AWS places a major strategic bet on agentic AI

AWS expands AI infrastructure, debuts agentic tools at re:Invent

by Neetu Chandra Sharma |Dec 3, 2025

AWS is entering a phase where companies will move beyond copilots and assistants to AI agents capable of completing full tasks across IT, operations, security, customer workflows and data-heavy enviro...

AWS extended its agentic-AI frameworks to regulated sectors

AWS expands tools for imaging, genomics and clinical data with 2025 upgrades

by Neetu Chandra Sharma |Dec 3, 2025

AWS also introduced the Trainium 3 chip and new AI-optimised servers designed to handle resource-intensive healthcare workloads such as genomics pipelines, biomarker discovery, molecular-simulation ta...

With its focus on promoting entrepreneurs, IIM Lucknow has emerged as the Start-Up School

With its focus on promoting entrepreneurs, IIM Lucknow has emerged as the Start-Up School

by Neetu Chandra Sharma |Dec 1, 2025

From adding courses in areas such as AI and sustainability to supporting more than 250 start-ups, IIML has been expanding steadily.

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India

Expect further innovation in cancer therapies: AstraZeneca Pharma India’s Praveen Rao Akkinepally

by Neetu Chandra Sharma |Nov 13, 2025

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, on new launches, India's expanding role in the global innovation pipeline, and more.

Next-gen of weight-loss drugs arriving sooner than expected

New weight-loss drugs set to shake up pharma in 2026

by Neetu Chandra Sharma |Nov 17, 2025

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.

U.S. Launches Drive Growth Momentum

U.S. Launches Drive Growth Momentum

by Neetu Chandra Sharma |Nov 12, 2025

Biocon Biologics is expanding its global biosimilars footprint, driven by new launches and market share gains in key therapy areas. The company’s U.S. presence has strengthened through partnerships su...

Novo Nordisk India Slashes Wegovy Price By 37% To Stay Ahead Of Rivals? Vikrant Shrotriya Answers

Novo Nordisk India Slashes Wegovy Price By 37% To Stay Ahead Of Rivals? Vikrant Shrotriya Answers

by Neetu Chandra Sharma |Nov 12, 2025

In an exclusive conversation with Business Today’s Neetu Chandra, Vikrant Shrotriya, Managing Director of Novo Nordisk India, discusses how the company is leading India’s obesity treatment revolution....

Price Cut Targets Wider Obesity Access

Novo Nordisk Announces Big Price Cut For Wegovy, Digs In To Woo Indian Customers

by Neetu Chandra Sharma |Nov 12, 2025

Novo Nordisk India has cut prices of its once-weekly obesity drug Wegovy (semaglutide) by 37%, bringing the starting dose down to ₹2,712 per week. The move aims to make evidence-based obesity treatmen...